c-MET antibody (Cytoplasmic Domain)

Catalog No. ABIN614469

Product Details anti-c-MET Antibody

Target: c-MET (MET) (Met Proto-Oncogene (MET))

Binding Specificity: Cytoplasmic Domain

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This c-MET antibody is un-conjugated

Application: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Specificity: Recognizes c-Met (Cytoplasmic Domain).

Cross-Reactivity (Details): Species reactivity (tested):Human.

Purification: Purified

Immunogen: Synthetic peptide derived from cytoplasmic domain of Human c-Met protein

Clone: IST-1

Isotype: IgG2a

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: PBS, 7.4 containing 1 % BSA and 0.09 % Sodium Azide

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.

Target Details for c-MET

Target: c-MET (MET) (Met Proto-Oncogene (MET))

Alternative Name: HGF Receptor (MET Products)

Synonyms: AUTS9 antibody, HGFR antibody, RCCP2 antibody, c-Met antibody, AI838057 antibody, HGF antibody, Par4 antibody, Hgfr antibody, c-met antibody, MET antibody, C-MET antibody, met antibody, met-A antibody, MET proto-oncogene, receptor tyrosine kinase antibody, met proto-oncogene antibody, MET proto-oncogene, receptor tyrosine kinase L homeolog antibody, MET antibody, Met antibody, met.L antibody

Background: The c-Met protein is a receptor tyrosine kinase encoded by the c-Met proto-oncogene. c-Met, also known as HGF receptor or SF receptor, is activated by hepatocyte growth factor (HGF) or scatter factor (SF), and is composed of alpha and beta subunits linked by disulfide bonds. Dysregulated c-Met expression has been detected at both protein and mRNA levels in a variety of human carcinomas and sarcomas. Up to a 2.5-fold increase in mRNA expression has been reported in colorectal tumor tissues, and upregulation of the c-Met protein in association with increasingly malignant behavior has been described in prostate cancer, cutaneous malignant melanoma, and breast cancer. Recent studies using monoclonal Ms anti-c-Met (clone: 3D4) for immunohistochemistry in lymph node-negative breast carcinoma tissues demonstrated that high levels of c-Met expression are associated with poor patient clinical outcome, as assessed over 20-40 years of follow-up. Further, antibodies against the intracellular but not the extracellular domain of c-Met were prognostic, suggesting that overexpression of the cytoplasmic tail of c-Met may play an important role in breast cancer progression.Synonyms: HGF/SF receptor, Hepatocyte growth factor receptor, MET, Met proto-oncogene tyrosine kinase, Scatter factor receptor, c-Met

Gene ID: 4233

NCBI Accession: NP_000236

UniProt: P08581

Pathways: RTK Signaling, Carbohydrate Homeostasis, Synaptic Membrane, Signaling of Hepatocyte Growth Factor Receptor